Microbot Medical stock holds at USD 2.14 after new data

Published on 09/23/2026 at 03:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Microbot Medical stock closed at USD 2.14 on September 22, 2026, with a market value of USD 18.7 million. The latest quarterly filing reported zero revenue.

MBOT, US5950101098, Illustration mit AI erstellt.

Microbot Medical stock (ISIN US5950101098) closed at USD 2.14 on Nasdaq on September 22, 2026, while the company carried a market capitalization of USD 18.7 million. The dated quote gives investors a concrete reference point for the medical-device developer.

Nasdaq valuation stays small

The September 22, 2026 market snapshot put the 52-week range at USD 1.61 to USD 4.25 and recorded 214,000 shares traded. The closing price stood USD 0.53 above the yearly low and USD 2.11 below the yearly high, leaving the stock 24.7 percent above its low and 49.6 percent below its high.

That spread is material for a company with a market capitalization of USD 18.7 million on September 22, 2026. A relatively small equity value means that operating milestones can have a pronounced effect on the market's assessment, while the 52-week range also shows the scale of the historical price movement.

Revenue remains the key operating figure

Microbot Medical's latest reported quarterly period showed revenue of USD 0 and a net loss of USD 6.2 million. The figures belong to the quarter reported in 2026 and put development spending, rather than recurring sales, at the center of the current operating picture.

The comparison is clear: revenue of USD 0 against a net loss of USD 6.2 million means the reported period produced no sales base against which commercial growth could be measured. For investors, the next measurable operating checkpoint is therefore the conversion of product development into revenue and a narrower loss.

Development stage shapes the risk

Microbot Medical develops intravascular robotic medical technology, so regulatory progress, clinical execution and financing capacity are central factors alongside the share price. The September 22, 2026 market value of USD 18.7 million reflects a small-cap profile in which quarterly cash use can matter as much as reported revenue.

The stock closed at USD 2.14 on Nasdaq on September 22, 2026. Its 52-week range of USD 1.61 to USD 4.25 and the latest quarterly revenue of USD 0 define the measurable operating and market backdrop.